BenzingaAugust 6, 2026 at 9:19 AM NY2 Months Ago
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
